Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.

[1]  B. Maron,et al.  Onset of apical hypertrophic cardiomyopathy in adulthood. , 2011, The American journal of cardiology.

[2]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[3]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[4]  L. Yeates,et al.  The emerging role of the cardiac genetic counselor. , 2011, Heart rhythm.

[5]  Michael J Ackerman,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[7]  J. Harper,et al.  Preimplantation genetic diagnosis: State of the ART 2011 , 2011, Human Genetics.

[8]  C. G. Donald,et al.  The Genetic Information Nondiscrimination Act of 2008 , 2011 .

[9]  L. Mestroni,et al.  Hearing the noise the challenges of human genome variation in genetic testing. , 2011, Journal of the American College of Cardiology.

[10]  Hugo A. Katus,et al.  Targeted Next-Generation Sequencing for the Molecular Genetic Diagnostics of Cardiomyopathies , 2011, Circulation. Cardiovascular genetics.

[11]  C. Semsarian,et al.  Molecular diagnostics of cardiomyopathies: the future is here. , 2011, Circulation. Cardiovascular genetics.

[12]  J. Seidman,et al.  Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. , 2011, Circulation research.

[13]  D. Tester,et al.  Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/Channelopathies in Clinical Practice , 2011, Circulation.

[14]  B. Maron,et al.  Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. , 2011, The American journal of cardiology.

[15]  A. Landstrom,et al.  Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy , 2010, Circulation.

[16]  Carolyn Y. Ho.  Genetics and Clinical Destiny: Improving Care in Hypertrophic Cardiomyopathy , 2010, Circulation.

[17]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[18]  W. Roberts,et al.  Profound left ventricular remodeling associated with LAMP2 cardiomyopathy. , 2010, The American journal of cardiology.

[19]  Barry J Maron,et al.  Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. , 2010, The American journal of cardiology.

[20]  J. Seidman,et al.  Genetics of hypertrophic cardiomyopathy , 2010, Current opinion in cardiology.

[21]  W. Chung,et al.  Short Communication: The Cardiac Myosin Binding Protein C Arg502Trp Mutation: A Common Cause of Hypertrophic Cardiomyopathy , 2010, Circulation research.

[22]  F. Cecchi,et al.  Cardiovascular events in patients with fabry disease natural history data from the fabry registry. , 2010, Journal of the American College of Cardiology.

[23]  W. Manning,et al.  Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy , 2010, Circulation.

[24]  I. V. van Langen,et al.  Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. , 2009, Heart rhythm.

[25]  W. Manning,et al.  Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.

[26]  R. Fanchin,et al.  Preimplantation genetic diagnosis: state of the art. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[27]  C. Semsarian,et al.  Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity? , 2009, Circulation. Cardiovascular genetics.

[28]  L. Hougs,et al.  Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives , 2009, Human mutation.

[29]  M. Beer,et al.  Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment , 2009 .

[30]  Ze-Zhou Song.  Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. , 2008, International journal of cardiology.

[31]  Rachael,et al.  Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. , 2008, Mayo Clinic proceedings.

[32]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[33]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[34]  Y. Pinto,et al.  Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. , 2006, Journal of the American College of Cardiology.

[35]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[36]  B. Maron,et al.  Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. , 2005, Journal of the American College of Cardiology.

[37]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[38]  Barry J Maron,et al.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[39]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[40]  V. Regitz-Zagrosek,et al.  Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy , 2003, Clinical genetics.

[41]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[42]  A. Tajik,et al.  Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. , 2002, Journal of the American College of Cardiology.

[43]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[44]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[45]  Carmel Shachar,et al.  Recent Developments in Health Law , 2000, Journal of Law, Medicine & Ethics.

[46]  H. Watkins.  Sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[47]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[48]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[49]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[50]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[51]  S. Solomon,et al.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. , 1989, The New England journal of medicine.

[52]  B. Maron,et al.  Heterogeneous Morphologic Expression of Genetically Transmitted Hypertrophic Cardiomyopathy: Two–dimensional Echocardiographic Analysis , 1983, Circulation.

[53]  E. Miadoková.  Genetics , 1977, Biologia Plantarum.

[54]  W. Henry,et al.  Asymmetric Septal Hypertrophy: Echocardiographic Identification of the Pathognomonic Anatomic Abnormality of IHSS , 1973, Circulation.

[55]  E. Braunwald,et al.  Idiopathic Hypertrophic Subaortic Stenosis: Clinical Analysis of 126 Patients with Emphasis on the Natural History , 1968, Circulation.

[56]  C. Lambrew,et al.  Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.

[57]  D TEARE,et al.  ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.

[58]  B. Maron,et al.  Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. , 2012, Heart rhythm.

[59]  J. Stockman.  Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy , 2011 .

[60]  J. Seidman,et al.  Clinical Outcome and Phenotypic Expression in LAMP 2 Cardiomyopathy , 2009 .

[61]  B. Maron,et al.  Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy , 2009 .

[62]  R. Bonow,et al.  36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities , 2005 .

[63]  A. Tajik,et al.  Prevalence and Severity of “Benign” Mutations in the β-Myosin Heavy Chain, Cardiac Troponin T, and α-Tropomyosin Genes in Hypertrophic Cardiomyopathy , 2002, Circulation.

[64]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[65]  C. Semsarian,et al.  Sudden cardiac death in familial hypertrophic cardiomyopathy: Are “benign” mutations really benign? , 1997, Pathology.